$IMRN News
Last published 1d ago
- 1d agoIMRNImmuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic InitiativesGlobeNewswireMELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at maximising shareholder value.
- 1d agoIMRNImmuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic InitiativesGlobeNewswireMELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation
- 1w agoIMRNEmerging Growth Research Reports Continued Revenue Growth at ImmuronACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / November 4, 2026 / Emerging Growth Research today announced the release of its company-sponsored research Flash Report on
- 2w agoIMRNEmerging Growth Conference 97 - IMMURON LTDEarnings Call Transcriptssee what we can answer today. So let's talk about your latest announcement identifies healthcare and senior living as potential markets for your guest intelligent platform. Are you already conducting pilot programs in th
- 2w agoIMRNImmuron continued quarterly sales growthGlobeNewswireSales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp)Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp)Q1 sales up
- 2w agoIMRNImmuron CEO, Steven Lydeamore presentation at Emerging Growth ConferenceGlobeNewswireMELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth
- 4w agoIMRNTravelan® Phase 2 Study Results PublishedGlobeNewswireMELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the
- 2mo agoIMRNImmuron to launch PROIBS® in the United StatesGlobeNewswireMELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with
- 2mo agoIMRNImmuron Reports FY26 Preliminary ResultsGlobeNewswireMELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectationsIn
- 2mo agoIMRNEarnings Call - IMMURON LTDEarnings Call TranscriptsWelcome back, everyone. We have an update from Imuron Limited. It trades on the NASDAQ under the symbol IMRN. It's a biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclona
- 2mo agoIMRNEmerging Growth Conference 95 - IMMURON LTDEarnings Call TranscriptsThank you for watching. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Piano music Thank you
- 2mo agoMWCSBCNPMMFSKHRF+20Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamGlobeNewswireMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth
- 2mo agoMWCSBCNPMMFSKHRF+20Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamGlobeNewswireMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging
- 3mo agoIMRNImmuron CEO, Steven Lydeamore presentation at Kalkine Media WebinarGlobeNewswireMELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar
- 3mo agoIMRNImmuron FY26 Sales - Four Consecutive Quarters of Growth over Prior YearGlobeNewswireSales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on pcp4Q FY26 sales AUD$2.0 million up 2% on pcp Australia
- 4mo agoIMRNImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering StrategyGlobeNewswireKey Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through regulatory approval and commercializationImmuron has U.S. Food and
- 6mo agoIMRNEmerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00ACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron , maintaining its Buy-Extended rating while increasing its 12-month price target to
- 6mo agoIMRNImmuron Double Digit 3Q Sales GrowthGlobeNewswireSales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up
- 8mo agoIMRNEmerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price TargetACCESS NewswireNEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited , maintaining its Buy-Extended rating and 12-month price target
- 8mo agoIMRNImmuron CEO, Steven Lydeamore presentation at Coffee Microcaps ConferenceGlobeNewswireMELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer,
- 8mo agoIMRNImmuron Reports HY26 Results and Strategic ResetGlobeNewswireHighlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD
- 9mo agoIMRNEmerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price TargetACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited , maintaining its Buy-Extended rating and 12-month price target of
- 9mo agoCBBHFCEIEFCLNNCOPAF+26Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live streamGlobeNewswireMIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth
- 9mo agoIMRNImmuron Reports Continued Sales GrowthGlobeNewswireSales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative
- 11mo agoIMRNImmuron New U.S. Department of Defense Award & Clinical Trial UpdateGlobeNewswireHighlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and ShigellaUniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025
- 1y agoIMRNImmuron IMM-529 IND approved by FDAGlobeNewswireKey Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529
- 1y agoIMRNImmuron Announces Clinical Trial UpdateGlobeNewswireIMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the
- 1y agoIMRNImmuron Q1 FY26 YoY growthGlobeNewswireSales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia•Q1 sales AUD$1.6 million up 52% on pcp Canada•Q1 sales AUD$0.0 million down 92% on pcp USA•Q1 sales
- 1y agoIMRNImmuron Submits IMM-529 IND to FDAGlobeNewswireKey Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical
- 1y agoIMRNImmuron Letter to Shareholders – Projects UpdateGlobeNewswireHighlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical
- 1y agoIMRNImmuron partners with InvestorHubGlobeNewswireMELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that
- 1y agoADVMCLNNCUAUFDERM+27Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamGlobeNewswireMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth
- 1y agoIMRNImmuron - FY25 global sales exceed projection, up 49% on prior yearGlobeNewswireSales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter
- 1y agoIMRNImmuron Letter to Shareholders: Projects UpdateGlobeNewswireHighlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan® clinical study in October 2025Immuron anticipates
- 1y agoIMRNImmuron Travelan® highest sales in historyGlobeNewswireSales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up
- 1y agoIMRNImmuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)GlobeNewswireMELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an
- 1y agoIMRNImmuron Travelan® continued strong sales growthGlobeNewswireSales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior
- 1y agoIMRNImmuron Announces New Research Collaboration targeting Antimicrobial ResistanceGlobeNewswireHighlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will focus on the
- 1y agoIMRNImmuron Announces Travelan® Clinical Trial UpdateGlobeNewswireHighlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology ResultsTravelan® (IMM-124E) Phase 2
- 1y agoIMRNImmuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5thGlobeNewswireMELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual
- 1y agoIMRNImmuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap EventGlobeNewswireMELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual
- 1y agoIMRNImmuron Limited to Present at November 21st Virtual Investor Summit Microcap EventACCESS NewswireMELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company
- 2y agoIMRNImmuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare ConferenceGlobeNewswireMELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim
- 2y agoIMRNImmuron Travelan® continued strong sales growthGlobeNewswireSales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica• September 2024 Quarter AUD$0.5 million up
- 2y agoIMRNNMRC Reports Results for Campylobacter Controlled Human Infection Model StudyGlobeNewswireMELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available
- 2y agoIMRNImmuron Plans Phase 2 Trial for IMM-529 following FDA reviewGlobeNewswireKey Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides
- 2y agoIMRNImmuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®GlobeNewswireHighlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE
- 2y agoIMRNImmuron CEO, Steven Lydeamore to present at the Emerging Growth ConferenceGlobeNewswireMELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive
- 2y agoIMRNImmuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct ConnectGlobeNewswireMELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday
- 2y agoIMRNImmuron announces record Travelan® sales globally, Australia and USAGlobeNewswireSales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7 million up 223% on pcp